10-Q: Protagonist Therapeutics Reports Strong Q1 2024 Results Driven by Takeda Collaboration

Protagonist Therapeutics reports a significant increase in revenue and a shift to profitability in Q1 2024, primarily due to a major collaboration agreement with Takeda Pharmaceuticals.

Summary

• Protagonist Therapeutics experienced a dramatic turnaround in Q1 2024, reporting a net income of $207.34 million compared to a net loss of $33.725 million in the same period last year.
• This shift to profitability was largely driven by a $254.953 million in license and collaboration revenue, primarily from the Takeda collaboration agreement.
• The company's total assets increased to $629.276 million, up from $357.951 million at the end of 2023, reflecting the influx of cash from the Takeda deal.
• Research and development expenses increased to $33.734 million, up from $27.416 million in Q1 2023, as the company continues to invest in its clinical programs.
• General and administrative expenses also rose to $14.910 million, up from $8.605 million in Q1 2023, due to increased advisory and legal fees related to the Takeda agreement.
• The company's cash, cash equivalents, and marketable securities totaled $322.6 million as of March 31, 2024.
• Protagonist has incurred cumulative net losses from inception through March 31, 2024 of $408.4 million.

Sentiment

Score: 8

Explanation: The document is very positive due to the significant increase in revenue and shift to profitability, driven by the Takeda collaboration. However, there are still risks associated with clinical development and the company's reliance on partnerships.

Positives

• The Takeda collaboration agreement provides a strong financial foundation for the company.
• The company has a significant amount of cash and marketable securities to fund operations.
• The company is eligible for substantial future milestone payments from both Takeda and JNJ.
• The company has a strong pipeline of peptide-based new chemical entities in advanced clinical development.
• The company has a proprietary discovery technology platform.

Negatives

• The company has incurred cumulative net losses of $408.4 million since inception.
• The company's future results of operations and liquidity could be adversely impacted by outbreaks of disease, epidemics and pandemics.
• The company is operating in a period of macroeconomic uncertainty and capital markets disruption.
• The company's financial position or results of operations may be adversely affected in the future due to numerous factors, including domestic and global monetary and fiscal policy, supply chain constraints, the ongoing conflicts between Russia and Ukraine and in Israel and surrounding areas and other factors.

Risks

• The company is heavily dependent on the success of its product candidates in clinical development.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company may require additional funding, which may not be available on acceptable terms.
• The company relies on JNJ and Takeda for the development and commercialization of its partnered product candidates.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company may face risks to its business arising from outbreaks of disease, epidemics and pandemics.
• Unstable market and economic conditions, including elevated and sustained inflation, may have serious adverse consequences on the company's business, financial condition and stock price.

Future Outlook

The company expects to announce top-line data for the VERIFY trial's 32-week primary efficacy endpoint by the end of the first quarter of 2025, potentially leading to an NDA filing in the fourth quarter of 2025. The company also expects to nominate a development candidate ready for Investigational New Drug enabling studies by the end of 2024.

Management Comments

• At JNJ's Enterprise Business Review in December 2023, JNJ highlighted JNJ-2113 as a potential firstand best-in class targeted oral IL-23 peptide antagonist with potential across multiple indications, including plaque psoriasis, psoriatic arthritis and inflammatory bowel disease, with potential peak year sales projection of $5.0 billion plus.

Industry Context

The collaboration with Takeda and the ongoing development of JNJ-2113 position Protagonist in the competitive landscape of biopharmaceutical companies focused on peptide-based therapeutics. The company is targeting large markets with significant unmet needs, such as polycythemia vera and inflammatory diseases.

Comparison to Industry Standards

• The company's shift to profitability in Q1 2024 is a significant achievement compared to many other clinical-stage biopharmaceutical companies that are still incurring losses.
• The $300 million upfront payment from Takeda is a substantial deal, indicating strong interest in the company's rusfertide program.
• The potential for $330 million in additional milestone payments from Takeda and $795 million from JNJ is also significant compared to other similar deals.
• The company's cash position of $322.6 million is relatively strong compared to other companies of similar size and stage of development.
• JNJ IL-23 monoclonal antibody drugs Stelara and Tremfya generated $14.0 billion in revenues in 2023, indicating the potential market size for JNJ-2113.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and potential for future growth.
• Employees may benefit from the company's increased financial stability and potential for expansion.
• Customers (patients) may benefit from the development of new and effective treatments for their conditions.
• Suppliers and creditors may benefit from the company's improved financial health and ability to meet its obligations.

Next Steps

• The company expects to announce top-line data for the VERIFY trial's 32-week primary efficacy endpoint by the end of the first quarter of 2025.
• The company expects to nominate a development candidate ready for Investigational New Drug enabling studies by the end of 2024.

Key Dates

Keywords

Protagonist Therapeutics, Takeda Pharmaceuticals, JNJ, rusfertide, JNJ-2113, collaboration agreement, clinical trials, biopharmaceutical, revenue, profitability, milestone payments, peptide therapeutics, hematology, immunomodulatory diseases